Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$596.92 USD

596.92
2,138,161

+3.13 (0.53%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Surmodics (SRDX) Q3 Earnings and Revenues Beat Estimates

Surmodics (SRDX) registered revenue growth in each of its core units viz. In Vitro Diagnostics and Medical Device in Q3.

Avanos Medical (AVNS) Q2 Earnings and Revenues Top Estimates

Avanos Medical's (AVNS) second-quarter results benefit from contribution from Chronic Care segment.

Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?

Is (TMO) Outperforming Other Medical Stocks This Year?

Illumina (ILMN) Q2 Earnings Miss Estimates, Margins Decline

Illumina (ILMN) exhibits dismal performance in the second quarter of 2020 due to pandemic-led business disruptions.

Nevro (NVRO) Q2 Loss Narrower than Expected, Revenues Beat

Nevro's (NVRO) domestic and international revenues declined on a year-over-year basis in Q2.

TMO vs. EW: Which Stock Is the Better Value Option?

TMO vs. EW: Which Stock Is the Better Value Option?

Cardiovascular Systems (CSII) Misses Q4 Earnings Estimates

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q2 earnings as patients avoid hospitals.

NuVasive's (NUVA) Q2 Earnings Beat Estimates, Revenues Miss

NuVasive's (NUVA) operating segments experienced slowdown in second-quarter volumes due to the coronavirus pandemic.

ResMed (RMD) Q4 Earnings & Revenues Top Estimates, Margins Up

ResMed's (RMD) top line reflects strong segmental and geographic performance boosted by pandemic-led demand growth for ventilators.

Varian (VAR) Earnings and Revenues Surpass Estimates in Q3

Varian's (VAR) Proton Solutions unit saw revenue growth in Q3.

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1

ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.

LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss

LHC Group's (LHCG) second-quarter results benefit from strength in hospice services.

Cardinal Health (CAH) Q4 Earnings Top Estimates, Revenues Lag

Cardinal Health's (CAH) fiscal fourth-quarter results reflect weak segmental performance.

Becton Dickinson (BDX) Earnings Surpass Estimates in Q3

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.

DENTSPLY SIRONA (XRAY) Q2 Earnings & Revenues Miss Estimates

DENTSPLY SIRONA's (XRAY) second-quarter 2020 results reflect weak segmental performance.

CVS Health (CVS) Q2 Earnings Top Estimates, 2020 View Up

CVS Health's (CVS) Health Care Benefits segment registers membership growth in Q2.

Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates

Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Down

Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.

Fresenius Medical (FMS) Q2 Earnings & Revenues Top Estimates

Fresenius Medical's (FMS) second-quarter earnings benefit from strong segmental performance.

AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal third-quarter earnings benefit from segmental growth.

Patterson Cos. (PDCO) Hits 52-Week High, Can the Run Continue?

Patterson Cos. (PDCO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Luminex (LMNX) Q2 Earnings Beat Estimates, Revenues Miss

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2

Inogen's (INGN) Q2 Earnings Beat Estimates, Revenues Miss

Inogen (INGN) saw growth in revenues within its Rental segment in Q2.

QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up

QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.

Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract

Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.